Trial Profile
PEG Intron/REBETOL Combination Therapy Special Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.; Schering-Plough
- 28 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Aug 2008 New trial record.